#HerantisPharma #phase1btrial #HER096 #Parkinsonsdisease #clinicaltrial #drugsafety #tolerability #pharmacokinetics #biomarkers #syntheticpeptidomimetic #cerebraldopamineneurotropicfactorprotein #CDNFprotein #MichaelJFoxFoundationforParkinsonsResearch #ParkinsonsUK
pharmatimes.com/news/heranti...
pharmatimes.com/news/heranti...
Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease - PharmaTimes
Trial progresses towards topline data expected later in the year
pharmatimes.com
May 21, 2025 at 12:13 PM